Lantheus' (LNTH) "Market Outperform" Rating Reaffirmed at JMP Securities

Lantheus (NASDAQ:LNTH - Get Free Report)'s stock had its "market outperform" rating restated by equities research analysts at JMP Securities in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $112.00 price objective on the medical equipment provider's stock. JMP Securities' price target suggests a potential upside of 20.92% from the company's previous close.

Other equities analysts have also recently issued research reports about the company. Truist Financial reissued a "buy" rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus price target of $131.86.

Lantheus Stock Performance

Shares of LNTH traded down $2.03 during mid-day trading on Tuesday, hitting $92.62. 620,047 shares of the company were exchanged, compared to its average volume of 836,343. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of 15.41 and a beta of 0.46. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a 50 day moving average of $89.98 and a 200-day moving average of $99.78.

Institutional Investors Weigh In On Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. Janus Henderson Group PLC grew its stake in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after buying an additional 257,022 shares during the period. Farallon Capital Management LLC grew its position in Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after acquiring an additional 796,000 shares during the period. Geode Capital Management LLC increased its stake in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Reinhart Partners LLC. raised its position in Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after purchasing an additional 123,282 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock valued at $99,525,000 after purchasing an additional 19,071 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.